With FDA Hold Continuing, Idenix To Focus On NS5A Inhibitor And New Uridine Nucleosides
This article was originally published in The Pink Sheet Daily
Executive Summary
HCV-focused biotech tells J.P. Morgan conference audience it is making IDX719, its Phase II NS5A inhibitor, its lead program and hopes to start a non-exclusive combination trial with another company’s protease inhibitor this year.
You may also be interested in...
Achillion Readies A Nuc Combo As Acquisition Speculation Swirls
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.
Achillion Readies A Nuc Combo As Acquisition Speculation Swirls
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.
AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program
AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.